Expanded access, also called compassionate use, is a potential pathway for patients with an immediate life-threatening or serious condition to gain early access to an investigational product for treatment outside of clinical trials when no comparable or satisfactory alternative therapy option is available. South Rampart Pharma is committed to developing transformative therapies in areas of significant unmet medical need to enhance the quality of life in patients dealing with acute and chronic pain. We believe the best way to make our therapies available in a timely manner to patients is through clinical trials. We are conducting clinical trials to assess the safety and efficacy of our investigational products, which if proven successful, will allow us to pursue approvals from regulatory authorities. South Rampart Pharma believes that participation in our clinical trials is the most timely and appropriate manner to access our investigational products prior to their approval, and the best way to expedite access to our drugs for appropriate patients. Therefore, South Rampart Pharma is not providing investigational products through expanded access at this time. South Rampart Pharma will continue to assess our expanded access policy and provide updates to this website. We are focused on advancing our clinical development programs, and more information about our clinical trials can be found on ClinicalTrials.gov. Please contact us with any questions at email@example.com.